Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 10, Issue 2, 2016, Pages S144-S149

  Mittal, Khyati ^a   Katare, Deepshikha Pande ^a  

^a AMITY UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Shared links; Type 2 diabetes mellitus; Type 3 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CHOLINE ACETYLTRANSFERASE; INSULIN RECEPTOR; INSULINASE; TAU PROTEIN;

ALZHEIMER DISEASE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; COMPLICATION; METABOLISM; MOLECULAR MODEL;

ALZHEIMER DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MODELS, MOLECULAR; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 85012839741     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2016.01.021     Document Type: Review

References (62)

1. Li, X., Song, D., Sean, X.L., Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. Clin Interv Aging, 10, 2015, 549.
2. Suzanne, M., Wands, R., Alzheimer's Disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2:6 (2008), 1101–1113.
3. Talbot, K., Wang, Y., Kazi, H., Han, Y., Bakshi, P., Stucky, A., Arnold, E., Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:4 (2012), 1316–1338.
4. Freude, S., Plum, L., Schnitker, J., Leeser, U., Udelhoven, M., Krone, W., et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54:12 (2005), 3343–3348.
5. Kulstad, J., Green, P.S., Cook, G., Watson, S., Reger, A., Baker, D., et al. Differential modulation of plasma (-amyloid by insulin in patients with Alzheimer disease. Neurology 66:10 (2006), 1506–1510.
6. Kroner, Z., The relationship between Alzheimer's disease and diabetes: type 3 diabetes?. Altern Med Rev, 14(4), 2009, 373.
7. Beeri, S., Schmeidler, J., Silverman, M., Gandy, S., Wysocki, M., Hannigan, M., et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71:10 (2008), 750–757.
8. Solano, C., Sironi, M., Bonfini, C., Solerte, B., Govoni, S., Racchi, M., Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14:7 (2000), 1015–1022.
9. Peila, R., Rodriguez, L., Launer, J., Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies The Honolulu-Asia Aging Study. Diabetes 51:4 (2002), 1256–1262.
10. Messier, C., Diabetes, Alzheimer's Disease and apolipoprotein genotype. Exp Gerontol 38:9 (2003), 41–946.
11. Akter, K., Lanza, A., Martin, A., Myronyuk, N., Rua, M., Raffa, B., Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?. Br J Clin Pharmacol 71:3 (2011), 365–376.
12. Suzanne, M., Type 3 diabetes is sporadic Alzheimer's disease: Mini-review. Eur Neuropsychopharmacol 24:12 (2014), 1954–1960.
13. Spielman, J., Little, P., Klegeris, A., Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J Neuroimmunol 273:1 (2014), 8–21.
14. Woods, C., Seeley, J., Baskin, G., Schwartz, W., Insulin and the blood-brain barrier. Curr Pharm Des 9:10 (2003), 795–800.
15. Craft, S., Peskind, E., Schwartz, W., Schellenberg, D., Raskind, M., Porte, D., Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease Relationship to severity of dementia and apolipoprotein E genotype. Neurology 50:1 (1998), 164–168.
16. Convit, A., Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26:1 (2005), 31–35.
17. Monte, D., Tong, M., Lester, N., Plater, M., Wands, Rs., Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimer's Dis 10:1 (2006), 89–109.
18. Rivera, J., Goldin, A., Fulmer, N., Tavares, R., Wands, R., Monte, D., et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of AD: link to brain reductions in acetylcholine. J Alzheimer's Dis 8:3 (2005), 247–268.
19. Felice, G., Lambert, P., Fernandez, S., Velasco, T., Lacor, N., Klein, L., AD-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging 29:9 (2008), 1334–1347.
20. Zhao, Q., Felice, G., Fernandez, S., Chen, H., Lambert, P., Quon, J., Klein, L., Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22:1 (2008), 246–260.
21. Gong, Y., Chang, L., Viola, L., Lacor, N., Lambert, P., Finch, E., Klein, L., AD-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci 100:18 (2003), 10417–10422.
22. Yamagishi, I., Ueda, S., Okuda, S., Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 13:27 (2007), 2832–2836.
23. Takeuchi, M., Yamagishi, S., Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. Med Hypotheses 63:3 (2004), 453–455.
24. Yamagishi, S., Takeuchi, M., Inagaki, Y., Nakamura, K., Imaizumi, T., Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23:4 (2002), 129–134.
25. Takeuchi, Masayoshi, Yamagishi, S., Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 14:10 (2008), 973–978.
26. Takeuchi, M., Sato, T., Takino, I., Kobayashi, Y., Furuno, S., Kikuchi, S., et al. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 69:6 (2007), 1358–1366.
27. Ando, K., Oishi, M., Takeda, S., Iijima, I., Isohara, T., Nairn, C., et al. Role of phosphorylation of Alzheimer's amyloid precursor protein during neuronal differentiation. J Neurosci 19:11 (1999), 4421–4427.
28. Bhat, V., Haeberlein, B., Avila, J., Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89:6 (2004), 1313–1317.
29. Kaneto, H., Matsuoka, A., Katakami, N., Kawamori, D., Miyatsuka, T., Yoshiuchi, K., et al. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 7:7 (2007), 674–686.
30. Thakur, A., Wang, X., Siedlak, L., Perry, G., Smith, A., Zhu, X., C-Jun phosphorylation in Alzheimer disease. J. Neurosci Res 85:8 (2007), 1668–1673.
31. Hak, E., Pols, A., Stehouwer, D., Meijer, J., Kiliaan, J., Hofman, A., Witteman, C., Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 86:9 (2001), 4398–4405.
32. Van, R., Huisman, M., Princen, H., Meinders, E., Kluft, C., Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 166:1 (2003), 129–135.
33. Hotamisligil, S., Inflammatory pathways and insulin action. Int J Obes 27 (2003), S53–S55.
34. Veurink, G., Fuller, J., Atwood, S., Martins, N., Review genetics, lifestyle and the roles of amyloid β and oxidative stress in Alzheimer's disease. Ann Hum Biol 30:6 (2003), 639–667.
35. Lue, F., Walker, G., Rogers, J., Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 22:6 (2001), 945–956.
36. Hull, M., Strauss, S., Berger, M., Volk, B., Bauer, J., The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behav Brain Res 78:1 (1996), 37–41.
37. Haan, N., Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2:3 (2006), 159–166.
38. Goodpaster, H., Krishnaswami, S., Harris, B., Katsiaras, A., Kritchevsky, B., Simonsick, M., et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch In Med 165:7 (2005), 777–783.
39. Campbell, W., Antidiabetic drugs present and future. Drugs 60:5 (2000), 1017–1028.
40. Gustafson, D., Rothenberg, E., Blennow, K., Steen, B., Skoog, I., An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Int Med 163:13 (2003), 1524–1528.
41. Razay, G., Vreugdenhil, A., Wilcock, G., The metabolic syndrome and Alzheimer disease. Arch Neurol 64:1 (2007), 93–96.
42. Han, W., Li, C., Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci 107:15 (2010), 6557–6558.
43. Craft, S., Stennis, G., Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3:3 (2004), 169–178.
44. Hong, M., Lee, Y., Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272:31 (1997), 19547–19553.
45. Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, K., et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:8 (2001), 759–767.
46. McShea, A., Harris, L., Webster, R., Wahl, F., Smith, A., Abnormal expression of the cell cycle regulators P16 and CDK4 in AD. Am J Pathol, 150(6), 1997, 1933.
47. Ogawa, O., Zhu, X., Lee, G., Raina, A., Obrenovich, E., Bowser, R., et al. Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe?. Acta Neuropathol 105:5 (2003), 524–552.
48. Harris, L., Zhu, X., Pamies, C., Rottkamp, A., Ghanbari, A., McShea, A., et al. Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes. Neurobiol Aging 21:6 (2000), 837–841.
49. Sultana, R., Butterfield, A., Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimer's Dis, 19(1), 2010, 341.
50. Stadtman, R., Protein oxidation in aging and age-related diseases. Ann NY Acad Sci 928:1 (2001), 22–38.
51. Sayre, M., Lin, D., Yuan, Q., Zhu, X., Tang, X., Protein adducts generated from products of lipid oxidation: Focus on HNE and ONE. Drug Metab Rev 38:4 (2006), 651–675.
52. Reddy, P., Zhu, X., Perry, G., Smith, A., Oxidative stress in diabetes and Alzheimer's disease. J Alzheimer's Dis 16:4 (2009), 763–774.
53. Yan, F., Barile, R., Agati, V., Du Yan, S., Ramasamy, R., Schmidt, M., The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 7:2 (2007), 146–153.
54. Chen, X., Walker, G., Schmidt, M., Arancio, O., Lue, F., Yan, D., RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 7 (2007), 735–742.
55. Wiklund, O., Håversen, L., Pettersson, C., Hultén, L., How can we prevent cardiovascular disease in diabetes. J Int Med 262:2 (2007), 199–207.
56. Reiman, M., Chen, K., Alexander, E., Caselli, J., Bandy, D., Osborne, D., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci 101:1 (2004), 284–289.
57. Kamboh, I., Apolipoprotein E polymorphism and susceptibility to AD. Hum Biol, 1995, 195–215.
58. Martins, J., Berger, T., Sharman, J., Verdile, G., Fuller, J., Martins, N., Cholesterol metabolism and transport in the pathogenesis of AD. J Neurochem 111:6 (2009), 1275–1308.
59. Hirsch-Reinshagen, V., Maia, F., Burgess, L., Blain, F., Naus, E., McIsaac, A., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 280:52 (2005), 43243–43256.
60. Moreira, I., Santos, S., Seiça, R., Oliveira, R., Brain mitochondrial dysfunction as a link between AD and diabetes. J Neurol Sci 257:1 (2007), 206–214.
61. Moreira, I., Santos, S., Sena, C., NunesE, Seiça, R., Oliveira, R., CoQ10 therapy attenuates amyloid β-peptide toxicity in brain mitochondria isolated from aged diabetic rats. Exp Neurol 196:1 (2005), 112–119.
62. Lovestone, S., Diabetes and dementia Is the brain another site of end-organ damage?. Neurology, 53(9), 1999, 1907.